Type II Heparin-Induced Thrombocytopenia: An Underrecognized Cause of Dialysis Catheter Dysfunction-A Case Report

被引：1

作者：

Karki, Sailesh ^{[1
]}

Aryal, Binit ^{[1
]}

Mainali, Arjun ^{[1
]}

Uprety, Navodita ^{[1
]}

Panigrahi, Kalpana ^{[2
]}

Adhikari, Samaj ^{[1
]}

机构：

[1] Interfaith Med Ctr, Internal Med, Brooklyn, NY 11213 USA

[2] One Brooklyn Hlth, Interfaith Med Ctr, Internal Med, Brooklyn, NY USA

来源：

CUREUS JOURNAL OF MEDICAL SCIENCE | 2023年 / 15卷 / 07期

关键词：

subcutaneous unfractionated heparin; unfractionated heparin; hypercoagulable state; hypercoagulable; thromboembolic events; dialysis catheter thrombosis; dialysis catheter dysfunction; thrombocytopenia; heparin induced thrombocytopenia (hit); HEMODIALYSIS-PATIENTS; ANTIBODIES;

D O I：

10.7759/cureus.41812

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Heparin-induced thrombocytopenia (HIT) is categorized into type 1 and type 2. It causes a decrease in platelet count during or shortly after exposure to heparin. Type 1 is mild and has a non-immune mechanism. Type 2 is a hypercoagulable state resulting from anti-heparin platelet factor 4 (PF4) IgG antibodies. These antibodies cause the activation of endothelium and thrombin generation. Type 2 HIT is complicated by life -threatening thromboembolic events such as deep venous thrombosis, pulmonary embolism, and myocardial infarction. HIT remains an under-recognized cause of dialysis catheter dysfunction and thrombosis. We present a case of a 66-year-old male with recurrent dialysis catheter thrombosis secondary to Type 2 HIT. Avoiding heparin-based dialysis or switching to non-heparin-based anticoagulation or peritoneal dialysis are the possible management strategies for such patients.

引用

页数：5

共 14 条

[1] Heparin induced thrombocytopenia: diagnosis and management update [J].

Ahmed, I. ;

Majeed, A. ;

Powell, R. .

POSTGRADUATE MEDICAL JOURNAL, 2007, 83 (983) :575-582

[2] American Society of Hematology 2018 guidelines for management of venous thromboembolism: heparin-induced thrombocytopenia [J].

Cuker, Adam ;

Arepally, Gowthami M. ;

Chong, Beng H. ;

Cines, Douglas B. ;

Greinacher, Andreas ;

Gruel, Yves ;

Linkins, Lori A. ;

Rodner, Stephen B. ;

Selleng, Sixten ;

Warkentin, Theodore E. ;

Wex, Ashleigh ;

Mustafa, Reem A. ;

Morgan, Rebecca L. ;

Santesso, Nancy .

BLOOD ADVANCES, 2018, 2 (22) :3360-3392

[3] Association of heparin-dependent antibodies and adverse outcomes in hemodialysis patients: A population-based study [J].

de la Vega, LP ;

Miller, RS ;

Benda, MM ;

Grill, DE ;

Johnson, MG ;

McCarthy, JT ;

McBane, RD .

MAYO CLINIC PROCEEDINGS, 2005, 80 (08) :995-1000

[4] Haemodialysis-related-heparin-induced thrombocytopenia: Case series and literature review [J].

Gameiro, Joana ;

Jorge, Sofia ;

Lopes, Jose Antonio .

NEFROLOGIA, 2018, 38 (05) :551-557

[5] Heparin-induced thrombocytopenia (HIT): Review of incidence, diagnosis, and management [J].

Hogan, Marie ;

Berger, Jeffrey S. .

VASCULAR MEDICINE, 2020, 25 (02) :160-173

[6] Heparin-induced thrombocytopenia in end-stage renal disease: Reliability of the PF4-heparin ELISA [J].

Kelly, Julie ;

Sylvester, Katelyn W. ;

Rimsans, Jessica ;

Bernier, Thomas D. ;

Ting, Clara ;

Connors, Jean M. .

RESEARCH AND PRACTICE IN THROMBOSIS AND HAEMOSTASIS, 2021, 5 (05)

[7]

Khalid S, 2017, CUREUS J MED SCIENCE, V9, DOI 10.7759/cureus.1428

[8] Anti-PF4/heparin antibodies associated with repeated hemofiltration-filter clotting: a retrospective study [J].

Lasocki, Sigismond ;

Piednoir, Pascale ;

Ajzenberg, Nadine ;

Geffroy, Arnaud ;

Benbara, Abdel ;

Montravers, Philippe .

CRITICAL CARE, 2008, 12 (03)

[9] Heparin-induced thrombocytopenia [J].

Lovecchio, F. .

CLINICAL TOXICOLOGY, 2014, 52 (06) :579-583

[10] Frequency of anti-heparin-platelet factor 4 antibodies in hemodialysis patients and correlation with recurrent vascular access thrombosis [J].

O'Shea, SI ;

Sands, JJ ;

Nudo, SA ;

Ortel, TL .

AMERICAN JOURNAL OF HEMATOLOGY, 2002, 69 (01) :72-73

← 1 2 →